- Home
- ICON vs CERO Comparison
ICON vs CERO Comparison
Compare ICON & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- CERO
- Stock Information
- Founded
- ICON 2023
- CERO 2017
- Country
- ICON Greece
- CERO United States
- Employees
- ICON N/A
- CERO 8
- Industry
- ICON
- CERO
- Sector
- ICON
- CERO
- Exchange
- ICON Nasdaq
- CERO Nasdaq
- Market Cap
- ICON 3.6M
- CERO 3.7M
- IPO Year
- ICON 2024
- CERO N/A
- Fundamental
- Price
- ICON $1.68
- CERO $0.45
- Analyst Decision
- ICON Strong Buy
- CERO Buy
- Analyst Count
- ICON 1
- CERO 2
- Target Price
- ICON $4.50
- CERO $3.00
- AVG Volume (30 Days)
- ICON 62.0K
- CERO 993.4K
- Earning Date
- ICON 06-17-2025
- CERO 05-15-2025
- Dividend Yield
- ICON 206.67%
- CERO N/A
- EPS Growth
- ICON N/A
- CERO N/A
- EPS
- ICON N/A
- CERO N/A
- Revenue
- ICON $5,309,000.00
- CERO N/A
- Revenue This Year
- ICON $76.76
- CERO N/A
- Revenue Next Year
- ICON $30.43
- CERO N/A
- P/E Ratio
- ICON N/A
- CERO N/A
- Revenue Growth
- ICON 18.61
- CERO N/A
- 52 Week Low
- ICON $1.60
- CERO $0.40
- 52 Week High
- ICON $154.00
- CERO $102.00
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- CERO 35.19
- Support Level
- ICON N/A
- CERO $0.42
- Resistance Level
- ICON N/A
- CERO $0.50
- Average True Range (ATR)
- ICON 0.00
- CERO 0.05
- MACD
- ICON 0.00
- CERO 0.00
- Stochastic Oscillator
- ICON 0.00
- CERO 24.77
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.